Compare Duolingo Inc (DUOL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Twist Bioscience Corp — how do they compare? Duolingo Inc trades at $151.56 (market cap $7.08B), while Twist Bioscience Corp trades at $154.2 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Twist Bioscience Corp for 27 Days on average.
| DUOL | TWST | |
|---|---|---|
Market Cap | $7.08B | $10.08B |
Volume | 729,171 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $341.08 | $205.00 |
52-Week Low | $90.03 | $25.45 |
Typical Hold Time | 137 Days | 27 Days |
Enterprise Value | $5.85B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $151.72, up 2.42% with a bullish technical signal. The stock shows strong fundamentals with revenue growth from $369M in 2022 to $1.04B in 2025 and net income surging to $414M. Recent earnings consistently beat expectations, though Q3 2026 results are pending. Analyst consensus is mixed with 37.5% buy ratings but a $140.63 price target below current levels. Operating cash flow reached $388M in 2025, supporting continued investment in user growth and AI capabilities.
Duolingo presents growth potential through AI-driven expansion and strong user metrics, but faces risks from insider selling and valuation concerns. The stock's current price exceeds analyst consensus, suggesting limited near-term upside. Key opportunities include market expansion beyond language learning, while risks involve competitive pressures and execution on monetization strategies.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
